Real-world efficacy of lenvatinib/pembrolizumab combination in anaplastic thyroid carcinoma: case series from two Italian referral centers
Authors' conclusion
Our study confirms the efficacy and safety of L + P therapy, identifying the CONUT score as a prognostic factor.
Study context
- Population
- Patients with anaplastic thyroid carcinoma (ATC) treated with lenvatinib plus pembrolizumab at two Italian referral centres
- Participants
- 16 patients
- Outcome
- OS, PFS, ORR and DCR (RECIST 1.1)
Methodological detailstwo Italian referral centres, real-world
- Two Italian referral centres
- Real-world
Main finding
As reported in the abstract
| Group | Median overall survival (OS) | Median progression-free survival (PFS) | Complete response | Partial response | Objective response rate (ORR) | Disease control rate (DCR) | Progressive disease |
|---|---|---|---|---|---|---|---|
| L + P | 10 months (95% CI: 4.2-15.9 months) | 6.0 months (95% CI: 0-12.7 months) | 6.2% | 31.3% | 37.5% | 68.8% | 25% |
L + P
Median overall survival (OS)10 months (95% CI: 4.2-15.9 months)
Median progression-free survival (PFS)6.0 months (95% CI: 0-12.7 months)
Complete response6.2%
Partial response31.3%
Objective response rate (ORR)37.5%
Disease control rate (DCR)68.8%
Progressive disease25%
Observational data: associations, not effects.
Further findings
| Outcome | P value |
|---|---|
| OS and PFS by baseline CONUT score (≤ 2 vs ≥ 3)CONUT ≤ 2 vs CONUT ≥ 3 · significantly longer OS with CONUT ≤ 2 | log-rank, P = 0.001 |
| OS and PFS by baseline CONUT score (≤ 2 vs ≥ 3)CONUT ≤ 2 vs CONUT ≥ 3 · longer PFS with CONUT ≤ 2 | P = 0.05 |
OS by baseline ECOG PS (0-2 vs ≥ 3)
- Non-significantly longer OS with baseline ECOG PS 0-2 vs ≥ 3
Original publication
Real-world efficacy of lenvatinib/pembrolizumab combination in anaplastic thyroid carcinoma: case series from two Italian referral centers. Eur Thyroid J. Published 13 April 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →